...
机译:VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS;
Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital;
Early OncologyLaboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCSLaboratory of Cancer GenomicsDepartment of Veterinary Medicine, University of MilanUnit of Gynecological Oncology Research, Istituto Europeo di Oncologia IRCCS;
BRCA; Cediranib; Olaparib; Ovarian cancer; PARP inhibitor; Patient-derived xenograft; VEGF pathway inhibitor;